{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:05:45Z","timestamp":1792195545049,"version":"4.4.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2015,7,20]],"date-time":"2015-07-20T00:00:00Z","timestamp":1437350400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1038\/nm.3910","type":"journal-article","created":{"date-parts":[[2015,7,20]],"date-time":"2015-07-20T12:01:08Z","timestamp":1437393668000},"page":"914-921","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":823,"title":["NY-ESO-1\u2013specific TCR\u2013engineered T cells mediate sustained antigen-specific antitumor effects in myeloma"],"prefix":"10.1038","volume":"21","author":[{"given":"Aaron P","family":"Rapoport","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward A","family":"Stadtmauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwendolyn K","family":"Binder-Scholl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Goloubeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2935-2566","authenticated-orcid":false,"given":"Dan T","family":"Vogl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon F","family":"Lacey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf Z","family":"Badros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Garfall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Finklestein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Kulikovskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjoy K","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shari","family":"Kronsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minnal","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Bond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Melchiori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna E","family":"Brewer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew B","family":"Gerry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J","family":"Pumphrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen K","family":"Tayton- Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilliam","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Holdich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saul","family":"Yanovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Hardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Yared","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naseem","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunita","family":"Philip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Westphal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don L","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce L","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bent K","family":"Jakobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kalos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0241-3557","authenticated-orcid":false,"given":"Carl H","family":"June","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,7,20]]},"reference":[{"key":"BFnm3910_CR1","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1182\/blood.V87.3.1196.bloodjournal8731196","volume":"87","author":"G Tricot","year":"1996","unstructured":"Tricot, G. et al. Graft-versus-myeloma effect: proof of principle. Blood 87, 1196\u20131198 (1996).","journal-title":"Blood"},{"key":"BFnm3910_CR2","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1182\/blood.V98.4.934","volume":"98","author":"E Alyea","year":"2001","unstructured":"Alyea, E. et al. T cell\u2013depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. Blood 98, 934\u2013939 (2001).","journal-title":"Blood"},{"key":"BFnm3910_CR3","doi-asserted-by":"publisher","first-page":"4362","DOI":"10.1182\/blood-2003-11-3862","volume":"103","author":"HM Lokhorst","year":"2004","unstructured":"Lokhorst, H.M. et al. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 103, 4362\u20134364 (2004).","journal-title":"Blood"},{"key":"BFnm3910_CR4","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1182\/blood.V89.3.789","volume":"89","author":"B Barlogie","year":"1997","unstructured":"Barlogie, B. et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 89, 789\u2013793 (1997).","journal-title":"Blood"},{"key":"BFnm3910_CR5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1056\/NEJM199607113350204","volume":"335","author":"M Attal","year":"1996","unstructured":"Attal, M. et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N. Engl. J. Med. 335, 91\u201397 (1996).","journal-title":"N. Engl. J. Med."},{"key":"BFnm3910_CR6","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1056\/NEJMoa022340","volume":"348","author":"JA Child","year":"2003","unstructured":"Child, J.A. et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N. Engl. J. Med. 348, 1875\u20131883 (2003).","journal-title":"N. Engl. J. Med."},{"key":"BFnm3910_CR7","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1182\/blood.V98.3.579","volume":"98","author":"LF Porrata","year":"2001","unstructured":"Porrata, L.F. et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood 98, 579\u2013585 (2001).","journal-title":"Blood"},{"key":"BFnm3910_CR8","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s10238-004-0041-4","volume":"4","author":"LF Porrata","year":"2004","unstructured":"Porrata, L.F. & Markovic, S.N. Timely reconstitution of immune competence affects clinical outcome following autologous stem cell transplantation. Clin. Exp. Med. 4, 78\u201385 (2004).","journal-title":"Clin. Exp. Med."},{"key":"BFnm3910_CR9","doi-asserted-by":"publisher","first-page":"13009","DOI":"10.1073\/pnas.202491499","volume":"99","author":"MV Dhodapkar","year":"2002","unstructured":"Dhodapkar, M.V., Krasovsky, J. & Olson, K. T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells. Proc. Natl. Acad. Sci. USA 99, 13009\u201313013 (2002).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm3910_CR10","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1158\/0008-5472.CAN-04-3337","volume":"65","author":"K Noonan","year":"2005","unstructured":"Noonan, K. et al. Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors. Cancer Res. 65, 2026\u20132034 (2005).","journal-title":"Cancer Res."},{"key":"BFnm3910_CR11","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1038\/nm1310","volume":"11","author":"AP Rapoport","year":"2005","unstructured":"Rapoport, A.P. et al. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat. Med. 11, 1230\u20131237 (2005).","journal-title":"Nat. Med."},{"key":"BFnm3910_CR12","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1182\/blood-2010-08-299396","volume":"117","author":"AP Rapoport","year":"2011","unstructured":"Rapoport, A.P. et al. Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. Blood 117, 788\u2013797 (2011).","journal-title":"Blood"},{"key":"BFnm3910_CR13","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1158\/1078-0432.CCR-13-2817","volume":"20","author":"AP Rapoport","year":"2014","unstructured":"Rapoport, A.P. et al. Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3\/poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells. Clin. Cancer Res. 20, 1355\u20131365 (2014).","journal-title":"Clin. Cancer Res."},{"key":"BFnm3910_CR14","doi-asserted-by":"publisher","first-page":"4499","DOI":"10.1158\/1078-0432.CCR-09-0418","volume":"15","author":"AP Rapoport","year":"2009","unstructured":"Rapoport, A.P. et al. Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of costimulated autologous T cells. Clin. Cancer Res. 15, 4499\u20134507 (2009).","journal-title":"Clin. Cancer Res."},{"key":"BFnm3910_CR15","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1182\/blood-2010-07-296822","volume":"117","author":"EA Stadtmauer","year":"2011","unstructured":"Stadtmauer, E.A. et al. Transfer of influenza vaccine-primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trial. Blood 117, 63\u201371 (2011).","journal-title":"Blood"},{"key":"BFnm3910_CR16","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.1158\/1078-0432.CCR-13-0282","volume":"19","author":"J Rosenblatt","year":"2013","unstructured":"Rosenblatt, J. et al. Vaccination with dendritic cell\/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin. Cancer Res. 19, 3640\u20133648 (2013).","journal-title":"Clin. Cancer Res."},{"key":"BFnm3910_CR17","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/nm1100","volume":"10","author":"SA Rosenberg","year":"2004","unstructured":"Rosenberg, S.A., Yang, J.C. & Restifo, N.P. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10, 909\u2013915 (2004).","journal-title":"Nat. Med."},{"key":"BFnm3910_CR18","doi-asserted-by":"publisher","first-page":"3174","DOI":"10.1002\/eji.201242606","volume":"42","author":"M Aleksic","year":"2012","unstructured":"Aleksic, M. et al. Different affinity windows for virus and cancer-specific T-cell receptors: implications for therapeutic strategies. Eur. J. Immunol. 42, 3174\u20133179 (2012).","journal-title":"Eur. J. Immunol."},{"key":"BFnm3910_CR19","doi-asserted-by":"publisher","first-page":"7308","DOI":"10.4049\/jimmunol.176.12.7308","volume":"176","author":"MA Purbhoo","year":"2006","unstructured":"Purbhoo, M.A. et al. Quantifying and imaging NY-ESO-1\/LAGE-1-derived epitopes on tumor cells using high affinity T cell receptors. J. Immunol. 176, 7308\u20137316 (2006).","journal-title":"J. Immunol."},{"key":"BFnm3910_CR20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.coi.2014.01.004","volume":"27","author":"D Mittal","year":"2014","unstructured":"Mittal, D., Gubin, M.M., Schreiber, R.D. & Smyth, M.J. New insights into cancer immunoediting and its three component phases\u2013elimination, equilibrium and escape. Curr. Opin. Immunol. 27, 16\u201325 (2014).","journal-title":"Curr. Opin. Immunol."},{"key":"BFnm3910_CR21","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude, S.L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507\u20131517 (2014).","journal-title":"N. Engl. J. Med."},{"key":"BFnm3910_CR22","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s12185-013-1479-5","volume":"99","author":"ML Davila","year":"2014","unstructured":"Davila, M.L. et al. Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies. Int. J. Hematol. 99, 361\u2013371 (2014).","journal-title":"Int. J. Hematol."},{"key":"BFnm3910_CR23","doi-asserted-by":"publisher","first-page":"p517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2014","unstructured":"Lee, D.W. et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385, p517\u2013p528 (2014).","journal-title":"Lancet"},{"key":"BFnm3910_CR24","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1126\/science.1129003","volume":"314","author":"RA Morgan","year":"2006","unstructured":"Morgan, R.A. et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126\u2013129 (2006).","journal-title":"Science"},{"key":"BFnm3910_CR25","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1182\/blood-2009-03-211714","volume":"114","author":"LA Johnson","year":"2009","unstructured":"Johnson, L.A. et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114, 535\u2013546 (2009).","journal-title":"Blood"},{"key":"BFnm3910_CR26","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1182\/blood-2009-01-199216","volume":"114","author":"WR Burns","year":"2009","unstructured":"Burns, W.R., Zheng, Z., Rosenberg, S.A. & Morgan, R.A. Lack of specific gamma-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation. Blood 114, 2888\u20132899 (2009).","journal-title":"Blood"},{"key":"BFnm3910_CR27","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/nbt1070","volume":"23","author":"Y Li","year":"2005","unstructured":"Li, Y. et al. Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat. Biotechnol. 23, 349\u2013354 (2005).","journal-title":"Nat. Biotechnol."},{"key":"BFnm3910_CR28","doi-asserted-by":"publisher","first-page":"6116","DOI":"10.4049\/jimmunol.180.9.6116","volume":"180","author":"PF Robbins","year":"2008","unstructured":"Robbins, P.F. et al. Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J. Immunol. 180, 6116\u20136131 (2008).","journal-title":"J. Immunol."},{"key":"BFnm3910_CR29","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1200\/JCO.2010.32.2537","volume":"29","author":"PF Robbins","year":"2011","unstructured":"Robbins, P.F. et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29, 917\u2013924 (2011).","journal-title":"J. Clin. Oncol."},{"key":"BFnm3910_CR30","doi-asserted-by":"crossref","unstructured":"Robbins, P.F. et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T cell receptor: Long term follow up and correlates with response. Clin. Cancer Res. (2014).","DOI":"10.1158\/1078-0432.CCR-14-2708"},{"key":"BFnm3910_CR31","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1056\/NEJMoa0800251","volume":"358","author":"NN Hunder","year":"2008","unstructured":"Hunder, N.N. et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N. Engl. J. Med. 358, 2698\u20132703 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnm3910_CR32","doi-asserted-by":"publisher","first-page":"20410","DOI":"10.1073\/pnas.0810114105","volume":"105","author":"J Yuan","year":"2008","unstructured":"Yuan, J. et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc. Natl. Acad. Sci. USA 105, 20410\u201320415 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm3910_CR33","first-page":"1156","volume":"94","author":"N van Baren","year":"1999","unstructured":"van Baren, N. et al. Genes encoding tumor-specific antigens are expressed in human myeloma cells. Blood 94, 1156\u20131164 (1999).","journal-title":"Blood"},{"key":"BFnm3910_CR34","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1182\/blood-2004-12-4931","volume":"106","author":"AA Jungbluth","year":"2005","unstructured":"Jungbluth, A.A. et al. The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3\/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood 106, 167\u2013174 (2005).","journal-title":"Blood"},{"key":"BFnm3910_CR35","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.4049\/jimmunol.178.5.3307","volume":"178","author":"M Condomines","year":"2007","unstructured":"Condomines, M. et al. Cancer\/testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysis. J. Immunol. 178, 3307\u20133315 (2007).","journal-title":"J. Immunol."},{"key":"BFnm3910_CR36","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1182\/blood-2006-04-014480","volume":"109","author":"D Atanackovic","year":"2007","unstructured":"Atanackovic, D. et al. Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Blood 109, 1103\u20131112 (2007).","journal-title":"Blood"},{"key":"BFnm3910_CR37","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.1182\/blood-2004-09-3707","volume":"105","author":"F van Rhee","year":"2005","unstructured":"van Rhee, F. et al. NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood 105, 3939\u20133944 (2005).","journal-title":"Blood"},{"key":"BFnm3910_CR38","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1093\/jnci\/djq310","volume":"102","author":"A Hoos","year":"2010","unstructured":"Hoos, A. et al. Improved endpoints for cancer immunotherapy trials. J. Natl. Cancer Inst. 102, 1388\u20131397 (2010).","journal-title":"J. Natl. Cancer Inst."},{"key":"BFnm3910_CR39","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee, D.W. et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124, 188\u2013195 (2014).","journal-title":"Blood"},{"key":"BFnm3910_CR40","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/MOP.0000000000000043","volume":"26","author":"DM Barrett","year":"2014","unstructured":"Barrett, D.M., Teachey, D.T. & Grupp, S.A. Toxicity management for patients receiving novel T-cell engaging therapies. Curr. Opin. Pediatr. 26, 43\u201349 (2014).","journal-title":"Curr. Opin. Pediatr."},{"key":"BFnm3910_CR41","doi-asserted-by":"publisher","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","volume":"118","author":"RJ Brentjens","year":"2011","unstructured":"Brentjens, R.J. et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118, 4817\u20134828 (2011).","journal-title":"Blood"},{"key":"BFnm3910_CR42","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1038\/mt.2014.148","volume":"22","author":"J Corrigan-Curay","year":"2014","unstructured":"Corrigan-Curay, J. et al. T-cell immunotherapy: looking forward. Mol. Ther. 22, 1564\u20131574 (2014).","journal-title":"Mol. Ther."},{"key":"BFnm3910_CR43","doi-asserted-by":"publisher","first-page":"TPS3102","DOI":"10.1200\/jco.2015.33.15_suppl.tps3102","volume":"33","author":"M Merchant","year":"2015","unstructured":"Merchant, M. et al. Genetically engineered NY-ESO-1 specific T cells in HLA-A201+ patients with advanced cancers. J. Clin. Oncol. 33, TPS3102 (2015).","journal-title":"J. Clin. Oncol."},{"key":"BFnm3910_CR44","doi-asserted-by":"publisher","first-page":"197ra103","DOI":"10.1126\/scitranslmed.3006034","volume":"5","author":"BJ Cameron","year":"2013","unstructured":"Cameron, B.J. et al. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci. Transl. Med. 5, 197ra103 (2013).","journal-title":"Sci. Transl. Med."},{"key":"BFnm3910_CR45","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","volume":"122","author":"GP Linette","year":"2013","unstructured":"Linette, G.P. et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 122, 863\u2013871 (2013).","journal-title":"Blood"},{"key":"BFnm3910_CR46","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.immuni.2013.07.002","volume":"39","author":"M Kalos","year":"2013","unstructured":"Kalos, M. & June, C.H. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity 39, 49\u201360 (2013).","journal-title":"Immunity"},{"key":"BFnm3910_CR47","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/nm.2088","volume":"16","author":"S Stein","year":"2010","unstructured":"Stein, S. et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat. Med. 16, 198\u2013204 (2010).","journal-title":"Nat. Med."},{"key":"BFnm3910_CR48","doi-asserted-by":"crossref","first-page":"5921","DOI":"10.4049\/jimmunol.159.12.5921","volume":"159","author":"BL Levine","year":"1997","unstructured":"Levine, B.L. et al. Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells. J. Immunol. 159, 5921\u20135930 (1997).","journal-title":"J. Immunol."},{"key":"BFnm3910_CR49","doi-asserted-by":"publisher","first-page":"132ra153","DOI":"10.1126\/scitranslmed.3003761","volume":"4","author":"J Scholler","year":"2012","unstructured":"Scholler, J. et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci. Transl. Med. 4, 132ra153 (2012).","journal-title":"Sci. Transl. Med."},{"key":"BFnm3910_CR50","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S1470-2045(11)70243-1","volume":"12","author":"A Krishnan","year":"2011","unstructured":"Krishnan, A. et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol. 12, 1195\u20131203 (2011).","journal-title":"Lancet Oncol."},{"key":"BFnm3910_CR51","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1200\/JCO.2012.48.4626","volume":"31","author":"P Sonneveld","year":"2013","unstructured":"Sonneveld, P. et al. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J. Clin. Oncol. 31, 3279\u20133287 (2013).","journal-title":"J. Clin. Oncol."},{"key":"BFnm3910_CR52","first-page":"1063","volume":"17","author":"P Richardson","year":"2003","unstructured":"Richardson, P. Novel strategies in the treatment of relapsed\/refractory multiple myeloma. From the Multiple Myeloma Research Foundation. Oncology 17, 1063\u20131065 (2003).","journal-title":"Oncology"},{"key":"BFnm3910_CR53","doi-asserted-by":"publisher","first-page":"4199","DOI":"10.1200\/JCO.2012.48.3685","volume":"31","author":"P Armand","year":"2013","unstructured":"Armand, P. et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J. Clin. Oncol. 31, 4199\u20134206 (2013).","journal-title":"J. Clin. Oncol."},{"key":"BFnm3910_CR54","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s00262-008-0620-4","volume":"58","author":"C Galustian","year":"2009","unstructured":"Galustian, C. et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer immunology immunotherapy 58, 1033\u20131045 (2009).","journal-title":"Cancer immunology immunotherapy"},{"key":"BFnm3910_CR55","first-page":"2427","volume":"118","author":"AG Ramsay","year":"2008","unstructured":"Ramsay, A.G. et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J. Clin. Invest. 118, 2427\u20132437 (2008).","journal-title":"J. Clin. Invest."},{"key":"BFnm3910_CR56","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","volume":"348","author":"TN Schumacher","year":"2015","unstructured":"Schumacher, T.N. & Schreiber, R.D. Neoantigens in cancer immunotherapy. Science 348, 69\u201374 (2015).","journal-title":"Science"},{"key":"BFnm3910_CR57","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","volume":"117","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar, S.V. et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 117, 4691\u20134695 (2011).","journal-title":"Blood"},{"key":"BFnm3910_CR58","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/j.1365-2141.2008.07374.x","volume":"143","author":"T Mark","year":"2008","unstructured":"Mark, T. et al. Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma. Br. J. Haematol. 143, 654\u2013660 (2008).","journal-title":"Br. J. Haematol."},{"key":"BFnm3910_CR59","doi-asserted-by":"crossref","first-page":"8463","DOI":"10.1128\/JVI.72.11.8463-8471.1998","volume":"72","author":"T Dull","year":"1998","unstructured":"Dull, T. et al. A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72, 8463\u20138471 (1998).","journal-title":"J. Virol."},{"key":"BFnm3910_CR60","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.immuni.2009.09.007","volume":"31","author":"S Janetzki","year":"2009","unstructured":"Janetzki, S. et al. \u201cMIATA\u201d-minimal information about T cell assays. Immunity 31, 527\u2013528 (2009).","journal-title":"Immunity"},{"key":"BFnm3910_CR61","doi-asserted-by":"publisher","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","volume":"3","author":"M Kalos","year":"2011","unstructured":"Kalos, M. et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3, 95ra73 (2011).","journal-title":"Sci. Transl. Med."},{"key":"BFnm3910_CR62","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1182\/blood-2009-04-217604","volume":"114","author":"HS Robins","year":"2009","unstructured":"Robins, H.S. et al. Comprehensive assessment of T cell receptor beta-chain diversity in alphabeta T cells. Blood 114, 4099\u20134107 (2009).","journal-title":"Blood"},{"key":"BFnm3910_CR63","doi-asserted-by":"crossref","unstructured":"Rizopoulos, D. Joint Models for Longitudinal and Time-to-Event Data (Chapman & Hall\/CRC, 2012).","DOI":"10.1201\/b12208"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nm.3910.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nm.3910","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nm.3910.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T06:18:59Z","timestamp":1691821139000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nm.3910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,20]]},"references-count":63,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["BFnm3910"],"URL":"https:\/\/doi.org\/10.1038\/nm.3910","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725653759.793511395","asserted-by":"object"}]},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,20]]},"assertion":[{"value":"30 January 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was funded in part by Adaptimmune Ltd., and the following authors are employed by Adaptimmune: G.K.B.-S., L.M., J.E.B., A.D.B., A.B.G., N.J.P., D.W., H.K.T.-M., L.R. and T.H.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}